

4:30 p.m. – 5:00 p.m.

## USP Biologics Stakeholder Forum 2022

## Collaborating to solve CMC challenges and support efficient development of lentiviral-mediated CAR T cell therapies

October 26, 2022, 9am – 5pm EDT at USP Headquarters in Rockville, MD USA



## Final Agenda

All times are in Eastern Daylight Time (EDT)

Onsite Registration and Information Meeting Center Foyer  USP Welcome and Opening Remarks Speaker: Maura C. Kibbey, Ph.D., Director, Biologics Marketing, Global Biologics, USP
Introduction and Objectives for today's Biologics Stakeholder Forum  Moderator: Edward Chess, Ph.D., USP Biologics Stakeholder Forum Planning Committee, Chair
USP standards to support the development of cell and gene therapy products Speaker: Ben Clarke, Ph.D., Senior Scientist II, Global Biologics, USP
Regulatory Considerations for the Development of Potency Assays during CAR T Cell Development  Speaker: Andrew Timmons, Ph.D., Biologist, U.S. Food and Drug Administration (FDA)
Approaches to Potency Testing for Chimeric Antigen Receptor T Cells Speaker: Shree Joshi, Senior Scientist, BioTD, Analytical Development, Janssen Pharmaceutical
Morning Break
Implementation of AQbD principles in potency assay development and overcoming challenges on the road to commercialization  Speaker: Kim Nguyen, Ph.D., Head of Product Attribute Sciences, Analytical Development, Kite Pharma
Q&A Panel Discussion  Moderator: Edward Chess, Ph.D.  Panelists Pan Chales Andrew Times and Share Leaking
Panelists: Ben Clarke, Andrew Timmons, and Shree Joshi  Lunch and networking break for in-person attendees
<ul> <li>Moderated Discussion</li> <li>Moderator: Kok-Seong (KS) Lim, Ph.D., Senior Director of Analytical Sciences and Quality Control, Metagenomi <ul> <li>Biological activity and potency</li> <li>Safety (replication-competent virus, integration, etc.)</li> </ul> </li> </ul>

Speaker: Linda Narhi, USP Biologics Stakeholder Forum Planning Committee, Vice-Chair

Next steps and closing remarks